



11-30-06

102W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ARHARYA et al. Examiner: Unknown  
Serial No.: 10/591,023 Group Art Unit: Unknown  
Filed: August 29, 2006 Docket: 11336.1022USWO  
Title: HERBAL EXTRACT FOR RENAL DISORDERS

CERTIFICATE UNDER 37 CFR 1.10  
Express Mail mailing label number: EV 802673430 US  
Date of Deposit: November 29, 2006

I hereby certify that the papers listed below are being deposited with the United States Postal Service Express Mail Post Office to Addressee service under 37 CFR 1.10 in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: April Miles  
Name: APRIL MILES

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**52835**  
PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.10.
- ☒ Information Disclosure Statement, Form 1449, 8reference(s).
- ☒ Other: International Search Report
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-3478. A duplicate of this sheet is enclosed.

Hamre, Schumann, Mueller & Larson, P.C.  
P.O. Box 2902 Minneapolis, MN 55402  
612.455-3800

By: [Signature]  
Name: Douglas P. Mueller  
Reg. No.: 30,300  
Initials: DPM:rkW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ACHARYA et al. Examiner: Unknown  
Serial No.: 10/591,023 Group Art Unit: Unknown  
Filed: August 29, 2006 Docket: 11336.1022USWO  
Title: HERBAL EXTRACT FOR RENAL DISORDERS

CERTIFICATE UNDER 37 CFR 1.10

Express Mail mailing label number: EV 802673430 US

Date of Deposit: November 29, 2006

I hereby certify that the papers listed below are being deposited with the United States Postal Service Express Mail Post Office to Addressee service under 37 CFR 1.10 in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: April Miles  
Name: APRIL MILES

INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. Copies of any foreign patent documents or "Other Documents" are enclosed. Please note that some of the references were cited in an International Search Report dated February 9, 2006. A copy is enclosed

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the Filing Date, before the mailing date of a First Office Action on the merits, or before the mailing date of a First Office Action on the merits after the filing of a request for continued examination under 37 C.F.R. §1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and
- ☐ the requisite Statement is below, OR

- ☐ the requisite fee of \$180.00 under Rule 1.17(p) is included herein, or
- ☐ (3) after the mailing date of a Final Rejection or Notice of Allowance but on or before the payment of the Issue Fee, AND
- ☐ the requisite Statement is below, AND
- ☐ the requisite fee of \$180.00 under Rule 1.17(p) is included herein.

### STATEMENT

As required under §1.97(e), Applicants hereby state either that:

- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

- ☐ If this box is checked, Applicant provides the following:

#### **Certification Under 37 C.F.R. §1.704(d)**

In accordance with 37 C.F.R. §1.704(d), the undersigned hereby certifies that each item listed on the enclosed Form 1449 was first cited in a communication from a foreign patent office in a counterpart application, and that this communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.

- ☐ The Examiner is hereby advised of the following co-pending U.S. applications. A copy of each U.S. patent application publication (if published) or application (if not published) is enclosed.

Application No.

Filing Date

Group

A concise explanation of the relevance of each non-English language document or other information is as follows (37 C.F.R. §1.98(a)(3)):

An English abstract has been provided for reference WO 91/08750.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or

otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

### **FEE AUTHORIZATION**

Should any fee associated with the submission of this paper not be attached hereto as a check, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 50-3478. Any overpayments should be credited to said Deposit Account.



Respectfully submitted,

HAMRE, SCHUMANN, MUELLER &  
LARSON, P.C.  
Post Office Box 2902  
Minneapolis, MN 55402-0902  
(612) 455-3800

Dated: November 29, 2006

By: \_\_\_\_\_

Douglas P. Mueller  
Reg. No. 30,300

DPM:rkw

<b>FORM 1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 11336.1022USWO	Application Number: 10/591,023
	Applicant: ACHARYA et al.	
	Filing Date: August 29, 2006	Group Art Unit: unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US 6,136,316	October 2000	MEHROTRA et al.			
	US 5,529,778	June 1996	ROHATGI			
	US 5,886,029	March 1999	DHALIWAL			
	US 6,274,595	August 2001	YOUNG et al.			
	US 5,486,160	January 1996	ROSSI et al.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02/053166	July 2002	WIPO				
	WO 91/08750	June 1991	WIPO			Abstract	
	183805	October 1998	INDIA				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		International Search Report for International Application No.: PCT/IB05/51103 dated February 9, 2006
		KUMAR, V. et al. Diuretic Activity of Herbal Nefroliv and Frusemide in Normal Rats. Phytomedica. 2002, Vol. 3, pages 73-75
		MEHER, S. K. et al. Nephroprotective effect of NEFROLIV (trademark) in Centainicin Induced Nephrotoxicity. Phytomedica. 2001, Vol. 2, No. 1-2, pages 41-47
		YI'E, U. M. et al. Immunotherapeutic Modification of Escheriehi coli Peritonitis and Bacteremia by Tinospora cordifolia. Journal of Postgraduate Medicine. 1992, Vol. 38, No. 1, pages 13-15
		THATTE, U. M. et al. Immunotherapeutic modification of experimental infections by Indain Medicinal Plants. Phytotherapy Research. 1989, Vol. 3, No. 2, pages 43-49
		KULLARNI et al. Study of the Immunostimulant Activity of Naphthoquinone Extract of Leaves of Lawsonia AAlba Linn. Indian Drugs. 1998 pages 427-433

**52835**

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	